Press release: dupixent approved in the us as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent approved in the us as the first new targeted therapy in over a decade for chronic spontaneous urticaria approval based on phase 3 studies demonstrating dupixent significantly reduced itch and hives compared to placebo in the us, there are more than 300,000 adults and adolescents aged 12 years and older living with csu who remain symptomatic despite antihistamine treatment csu is the seventh disease with underlying type 2 inflammation in which dupixent is approved paris and tarrytown, ny, april 18, 2025. the us food and drug administration (fda) has approved dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (csu) who remain symptomatic despite histamine-1 (h1) antihistamine treatment.
REGN Ratings Summary
REGN Quant Ranking